Hims & Hers Health, Inc. (NYSE:HIMS – Get Rating) Director Jules A. Maltz bought 75,000 shares of the stock in a transaction dated Tuesday, June 14th. The stock was purchased at an average price of $3.66 per share, with a total value of $274,500.00. Following the acquisition, the director now directly owns 125,000 shares in the company, valued at approximately $457,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
HIMS traded up $0.03 on Thursday, reaching $4.10. 2,188,427 shares of the company traded hands, compared to its average volume of 2,258,434. Hims & Hers Health, Inc. has a one year low of $2.72 and a one year high of $12.22. The firm has a fifty day simple moving average of $4.15 and a two-hundred day simple moving average of $4.91. The company has a market cap of $840.80 million, a P/E ratio of -11.31 and a beta of 0.38.
Hims & Hers Health (NYSE:HIMS – Get Rating) last announced its quarterly earnings data on Monday, May 9th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. Hims & Hers Health had a negative net margin of 22.60% and a negative return on equity of 22.41%. The company had revenue of $101.30 million during the quarter, compared to analyst estimates of $90.99 million. During the same quarter last year, the business posted ($0.14) EPS. The firm’s revenue for the quarter was up 93.7% on a year-over-year basis. Equities research analysts expect that Hims & Hers Health, Inc. will post -0.35 earnings per share for the current year.
Whether you’re looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today’s futures markets!
Large investors have recently bought and sold shares of the company. Redpoint Management LLC bought a new stake in shares of Hims & Hers Health in the 4th quarter valued at about $68,095,000. Chiron Capital Management LLC bought a new stake in shares of Hims & Hers Health in the 4th quarter valued at about $90,000. Citigroup Inc. raised its holdings in shares of Hims & Hers Health by 409.4% in the 3rd quarter. Citigroup Inc. now owns 25,554 shares of the company’s stock valued at $193,000 after purchasing an additional 20,538 shares in the last quarter. California State Teachers Retirement System purchased a new position in shares of Hims & Hers Health in the 3rd quarter worth approximately $453,000. Finally, EPIQ Capital Group LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter worth approximately $121,000. Institutional investors and hedge funds own 57.22% of the company’s stock.
Several research firms have recently issued reports on HIMS. Deutsche Bank Aktiengesellschaft began coverage on shares of Hims & Hers Health in a report on Thursday, March 10th. They issued a “hold” rating and a $7.00 target price for the company. Citigroup lowered their target price on shares of Hims & Hers Health from $9.00 to $6.00 in a report on Tuesday, May 10th. Piper Sandler lowered their target price on shares of Hims & Hers Health from $8.00 to $6.00 and set an “overweight” rating for the company in a report on Thursday, May 26th. Finally, Guggenheim began coverage on shares of Hims & Hers Health in a report on Wednesday, April 13th. They issued a “buy” rating and a $10.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $8.00.
Hims & Hers Health Company Profile (Get Rating)
Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Hims & Hers Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Hims & Hers Health wasn’t on the list.
While Hims & Hers Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.